{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "SOPH",
  "name": "SOPHiA GENETICS SA",
  "url": "https://frontierpicks.com/dossiers/SOPH/",
  "json_url": "https://frontierpicks.com/dossiers/SOPH.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a3",
    "n": 3
  },
  "current_thesis": "SOPHiA GENETICS' cloud-genomics expansion thesis requires renewed strength above the $8.92 market high and another revenue-guidance increase at Q3 results, estimated for 2026-11-03. A weekly close below $6.84 invalidates the price thesis; unchanged or lower FY2026 guidance would fail the operating test.",
  "invalidation_trigger": "A weekly close below $6.84 loses the 2026-08-04 post-results reference close; separately, Q3 results estimated for 2026-11-03 that leave FY2026 revenue guidance at $94–96 million or lower, or report net dollar retention below 110%, invalidate the operating case.",
  "catalyst_date": "2026-09-22",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics",
    "ai-enterprise-software"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Foreign private issuer: reports on Form 6-K and 20-F rather than 10-Q/10-K, so interim disclosure is lighter than at US-domiciled diagnostics comparables.",
    "FPI insiders are exempt from Section 16, so there is no Form 4 record — insider buying or selling is not observable for this name.",
    "Swiss issuer reporting in USD: Q2 2026 reported growth (27%) exceeded constant currency (25%), so FX moves the headline against the $94–96M guide.",
    "Adjusted EBITDA excludes share-based compensation: the Q2 2026 adjusted EBITDA loss of $8.8M sits against a $22.4M net loss.",
    "further shelf issuance remains possible."
  ],
  "body_markdown": "## Current Thesis\n\nSOPHiA GENETICS' cloud-genomics expansion thesis depends on renewed price strength above the market's $8.92 high and a further revenue-guidance increase at the next quarterly report. The operating foundation remains the 2026-08-04 results: net dollar retention of 117%, compared with 107% a year earlier, and FY2026 revenue guidance raised to $94–96 million. The AstraZeneca collaboration announced that day covers two companion-diagnostic programs; it establishes a named commercial relationship, but does not by itself establish future revenue.\n\nThe September refresh shows consolidation rather than a confirmed new advance. The supplied adjusted market series closed at $8.19 on 2026-09-18, compared with $8.09 on 2026-09-04, while the 14-day relative strength index (RSI) eased to 50.8 from 56.8. As an inference from those observations, the narrative is maturing — August's operating improvement remains the anchor, while the September price observations do not establish accelerating participation. A weekly close above the $8.92 high would challenge that classification; a weekly close below $6.84 would invalidate the price thesis.\n\n## Bull Case\n\n- **Existing customers expanded their spending.** The company's 2026-08-04 results reported Q2 net dollar retention of 117%, versus 107% a year earlier. That supports the expansion thesis within the installed customer base; durability remains unproven beyond the reported quarter.\n- **Activity and customer counts increased.** The 2026-08-04 release reported 542 core genomics customers versus 490 a year earlier, alongside 115,000 quarterly analyses, up 22% year over year. These are operating measures supporting the platform narrative.\n- **Revenue supported a higher outlook.** Q2 2026 revenue was $23.310 million, up 27% reported and 25% in constant currency, according to the 2026-08-04 release. Management increased FY2026 revenue guidance to $94–96 million from $92–94 million.\n- **Pharma collaboration has defined programs.** The 2026-08-04 AstraZeneca announcement identified a decentralized solid-tumour companion diagnostic and a hematological oncology test. The supplied announcement contains no contract-value figure, so its revenue contribution cannot be quantified here.\n\n## Bear Case\n\n- **Margins weakened despite higher activity.** The 2026-08-04 results reported Q2 adjusted gross margin of 72.1%, versus 74.4% a year earlier, citing cloud costs, services mix and project ramps. Another quarter at or below 72.1% would undermine the operating-leverage interpretation.\n- **Losses remain material against revenue.** The same 2026-08-04 release reported a Q2 net loss of $22.4 million and an adjusted loss before interest, taxes, depreciation and amortization of $8.8 million. The adjusted measure does not establish cash consumption or profitability.\n- **Equity funding expanded the share supply.** The company's 2026-06-19 closing announcement reported $57.5 million in gross offering proceeds, including full exercise of the underwriters' option. This is documented financing, not evidence of subsequent market selling. [Company offering announcement](https://www.sec.gov/Archives/edgar/data/1840706/000119312526276865/d25509dex993.htm).\n- **Lock-up expiry is newly relevant.** MarketScreener reported on 2026-09-14 that restrictions on certain options and restricted share units ended on 2026-09-15. Expiry alone establishes neither exercise nor disposal. [Dated lock-up report](https://www.marketscreener.com/news/certain-options-of-sophia-genetics-sa-are-subject-to-a-lock-up-agreement-ending-on-15-sep-2026-ce785bddd989f423).\n\n## Setup & Price Structure\n\nThe 2026-09-18 adjusted reference close of $8.19 was 8.2% below the supplied 52-week high of $8.92, after a three-month price increase of 53.4%. The market's 2026-08-21 close of $8.65 remains an intermediate reference, while the 2026-08-04 post-results close of $6.84 remains the thesis-break level. A weekly close above $8.92 would satisfy the price component of the continuation case; the observations supplied do not establish that breakout.\n\nPublic attention is observable, but crowding is not established. Zacks published a momentum article on 2026-09-18 that attributed renewed interest to the previously reported Q2 performance. That attribution is Zacks' interpretation, and one article cannot establish retail-sentiment clustering. [Zacks coverage](https://www.zacks.com/stock/news/2991745/sophia-genetics-soph-moves-70-higher-will-this-strength-last?art_rec=blog-fundamental_analysis-up_next-ID01-txt-2991745).\n\nThe company's filing index lists Form 4 reports dated 2026-08-31, so a blanket assertion that no insider-reporting record exists is unsupported. The index alone does not establish transaction direction, motivation or aggregate insider selling. No moving-average value or short-interest measure is supplied for 2026-09-18. [Company filing index](https://ir.sophiagenetics.com/sec-filings?cat=5&year=2026).\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-22 to 2026-09-23 — Americas Innovation Summit.** The company calendar lists the Nashville event for clinicians, researchers and biopharma participants. Its scheduled occurrence does not establish a financial disclosure; an announcement would need explicit commercial terms to change the revenue assessment. [Company event calendar](https://www.sophiagenetics.com/events-and-webinars/).\n- **2026-10-05 to 2026-10-08 — World CB & CDx Boston.** The company calendar identifies this clinical-biomarker and companion-diagnostics event. It is relevant to the programs announced with AstraZeneca on 2026-08-04, but attendance itself does not confirm monetization. [Company event calendar](https://www.sophiagenetics.com/events-and-webinars/).\n- **~2026-11-03, estimated — Q3 2026 results.** This later event is the operating test of the thesis. MarketBeat explicitly labels the date estimated; company confirmation is missing. The report would establish whether retention sustains August's improvement and whether the $94–96 million FY2026 revenue range rises again. [Estimated earnings calendar](https://www.marketbeat.com/stocks/NASDAQ/SOPH/earnings/).\n\n## What Would Change Our Mind\n\nLoss of the August results reference would break the price structure: a weekly close below $6.84, the 2026-08-04 post-results close, ends the continuation thesis. This is an analytical condition tied to the public adjusted price series.\n\nThe operating case requires a second improvement in expectations. At the Q3 report estimated for 2026-11-03, an unchanged or lower $94–96 million FY2026 revenue range would fail that test; net dollar retention below 110% would separately contradict sustained customer expansion. These are prospective research conditions, not company guidance. Retention at least matching Q2's 117%, a higher annual revenue range and adjusted gross margin above Q2's 72.1% would provide the operating confirmation presently missing.\n\n## Correlation Notes\n\nThis remains a single-company setup in the 2026-09-20 assessment: no active peer cluster or paired return series is supplied. The evidence is insufficient to claim a measured correlation with artificial-intelligence software or diagnostics shares. The relevant company-specific exposures are the genomics activity and AstraZeneca programs disclosed on 2026-08-04.\n\nCurrency is a documented reporting exposure. Q2 2026 revenue growth was 27% reported versus 25% in constant currency in the 2026-08-04 release. That difference does not establish an equity-price correlation with the dollar, and no such coefficient is available.",
  "first_seen": "2026-08-23",
  "last_analyzed": "2026-09-20T12:49:54+00:00",
  "last_synthesized": "2026-09-20",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}